Study of MHB018A for active thyroid eye disease
Treatments studied
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new medicine called MHB018A for people with active, moderate to severe thyroid eye disease. It aims to see if the drug can reduce eye symptoms like bulging and inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have active thyroid eye disease with a clinical activity score of 3 or more in the affected eye.
- Your thyroid eye disease is moderate to severe.
- You do not need immediate eye surgery and are not planning any corrective surgery or radiation during the trial.
- If you have diabetes, it must be well-controlled.
- If you could become pregnant, you must use reliable birth control and have a negative pregnancy test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new sequence of hormone therapy followed by a targeted drug (tetuzumab) for people with moderate to severe thyroid eye disease that is still active after steroid treatment didn't help enough.
This trial tests a medication called IBI311 for people with inactive thyroid eye disease that still causes bothersome symptoms like double vision or trouble closing the eyes. The goal is to see if it helps improve these problems safely.
This study tests a new medication called MHB018A for people with chronic Thyroid Eye Disease (TED) that is moderate to severe. It aims to see if the drug can help improve symptoms and quality of life over time.
This study tests a longer-term use of MHB018A for people with thyroid eye disease who did not fully respond to treatment in a previous study. It aims to see if further treatment can help improve eye bulging and other symptoms.
This trial tests a new medication, KHN939, for people with moderate-to-severe active thyroid eye disease. It aims to reduce eye bulging and other symptoms.
This trial tests a new drug, KHN939, for people with moderate-to-severe thyroid eye disease that is no longer active. It aims to see if the drug can improve symptoms like bulging eyes, eyelid retraction, or double vision.
Hear when a new Thyroid Associated Ophthalmopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.